Tumors handle fuel differently from the tissue around them, and that difference is measurable and useful. It is also the starting point for one of the most persistent claims in the wellness world: that sugar feeds cancer and cutting carbohydrate can starve it. The biology is well established.
The dietary conclusion drawn from it is not supported by human trials. This page separates the two: what cancer metabolism is, why your bloodstream keeps its glucose in a narrow band whatever you eat, and where metabolic health does affect cancer, which is the risk of developing one, not the treatment of one you already have.
Findings & Outcomes
The Warburg Effect
In the 1920s Otto Warburg noticed that tumor tissue consumed glucose at a striking rate and poured out lactate even when oxygen was freely available. Normal cells mostly reserve that fermentation route for when oxygen is short. Many cancers use it all the time. This pattern, aerobic glycolysis, is now called the Warburg effect, and it is one of the better established facts in cancer biology.
The modern reading of why is not that tumors are starved of oxygen or short of working mitochondria. A dividing cell needs raw material as much as it needs energy: the carbon and nitrogen to build new membranes, nucleotides and proteins for two cells where there was one. Running glucose only partway through glycolysis, instead of oxidizing it fully, leaves those building blocks available. The Warburg effect is the metabolism of a cell committed to growth.
Altered metabolism is part of mainstream oncology, not a fringe idea. The widely used hallmarks-of-cancer framework lists reprogrammed energy metabolism among the core capabilities a cancer acquires, alongside the driver mutations, not in place of them.
It is also exploited every day in the clinic. A PET scan uses a radioactive glucose analogue, FDG, which accumulates where glucose uptake is highest, so FDG-PET locates many tumors and is a routine tool for staging and follow-up.
Does Sugar Feed Cancer
Here is the leap that does not hold. From the true statement that tumor cells take up a lot of glucose, a much larger claim is drawn: that eating sugar feeds your cancer, and that cutting carbohydrate will starve it. The step from the first to the second is where the reasoning breaks.
Your body holds blood glucose in a narrow range whatever you eat, because a steady supply is non-negotiable for the brain and red blood cells:
- Eat more sugar and insulin rises to store the excess.
- Eat none and the liver manufactures glucose from other sources.
- Either way, blood glucose stays in that narrow band, and a tumor draws what it needs from the regulated bloodstream it sits in.
Cutting dietary sugar does not lower the glucose a tumor sees to anywhere near the degree the slogan imagines, because the body will not let blood glucose fall that far while it can prevent it. This is why "sugar feeds cancer" fails as a plan. The fact it rests on is true, and the diet it recommends does not act on the thing it claims to.
None of this makes sugar harmless. A diet heavy in sugar promotes weight gain, and excess body fat is itself a cancer risk factor, covered below. That is a different pathway: sugar can raise cancer risk through what it does to body weight over years, which is a separate thing from sugar directly feeding an existing tumor at the dinner table.
The Metabolic Theory And Its Limits
There is a serious version of the metabolic argument, and it deserves to be stated fairly. A minority view, associated most prominently with Thomas Seyfried, holds that cancer is primarily a metabolic disease of the mitochondria, with the genetic mutations a downstream consequence and not the root cause, and that a ketogenic diet could therefore be a therapy in its own right. The mainstream view is that cancer is driven by mutations in genes that control growth, with the metabolic reprogramming this page describes as one of the capabilities that follow. These two accounts make different predictions, and the difference can be tested.
On the question that matters to a patient, whether a ketogenic diet treats established cancer, the human evidence has been examined. Systematic reviews of ketogenic diets in cancer patients have found no adequate evidence that the diet slows tumor growth or improves survival. A 2021 meta-analysis reported no benefit on antitumor therapy. The trials so far have been small, short and mixed in design, and a strict ketogenic diet is hard to sustain during treatment. There are preclinical signals and some adjunct hypotheses under active study, and several trials are ongoing. No human trial shows that a ketogenic or low-sugar diet cures or treats cancer. That claim sits at not established.
No ketogenic or low-sugar diet has been shown in a human trial to treat cancer or improve survival. Used in place of proven treatment, it can cost someone the window when that treatment works.
The safety consequence follows directly. A ketogenic diet marketed as a cancer treatment can lead someone to eat in a way that causes weight loss and muscle wasting at exactly the point in illness when maintaining weight matters most, and worse, to delay or refuse treatment that works. The seriousness of that harm is why this claim is graded strictly.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Many tumors burn glucose fast and pour out lactate even with oxygen, the Warburg effect
Cancer cells often burn glucose fast and messily even when they have plenty of oxygen. This is the Warburg effect, and it is a real, well-established feature of many tumors.
Aerobic glycolysis, the Warburg effect, describes tumor cells consuming glucose at high rates and producing lactate despite adequate oxygen, whereas most normal cells reserve fermentation for low-oxygen conditions. The modern interpretation is that a rapidly dividing cell needs biosynthetic precursors (carbon and nitrogen for membranes, nucleotides and proteins) as much as it needs ATP, and running glucose partway through glycolysis leaves those intermediates available. It is understood as the metabolism of a cell committed to growth rather than as evidence of mitochondrial failure.
The study · 1
Vander Heiden, Cantley & Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation · Science 2009;324(5930):1029-33
Reprogrammed energy metabolism is one of the recognized hallmarks of cancer
Altered metabolism is part of mainstream cancer biology, not a fringe idea. The standard hallmarks framework counts it as one of the core things a cancer does, sitting next to the genetic mutations.
The 2011 hallmarks-of-cancer update added reprogramming of energy metabolism (deregulated cellular energetics) to the set of capabilities a cancer acquires as it develops. This situates the metabolic changes this page describes within the dominant genetic model of cancer: mutations in growth-controlling genes are treated as the driving events, and metabolic reprogramming is one of the enabling capabilities that follows and interacts with them. It is a framework statement rather than a single experimental result.
The study · 1
Hanahan & Weinberg, Hallmarks of cancer: the next generation · Cell 2011;144(5):646-74
Cancer Risk And Outcome
Excess body fat raises the risk of thirteen cancers (IARC)
Carrying excess body fat over the long term is one of the most firmly established causes of cancer, raising the risk of thirteen different cancers by IARC's assessment.
The International Agency for Research on Cancer convened a Working Group that reviewed over a thousand studies and concluded the evidence was sufficient for a cancer-preventive effect of the absence of excess body fatness for thirteen cancer types: colon and rectum, esophagus (adenocarcinoma), gastric cardia, liver, gallbladder, pancreas, postmenopausal breast, corpus uteri (endometrium), ovary, kidney (renal cell), meningioma, thyroid and multiple myeloma. This expanded the list of five cancers identified in the agency's earlier 2002 evaluation.
Who this may not transfer to:A population risk factor drawn from studies across both sexes; it concerns the chance of developing cancer, not the treatment of one that already exists.
The study · 1
Lauby-Secretan et al. (IARC Working Group), Body fatness and cancer · N Engl J Med 2016;375(8):794-8
Adjuvant metformin did not improve breast cancer survival in 3,649 patients (MA.32)
The largest trial to test it found that adding the diabetes drug metformin to standard breast cancer treatment did not improve survival.
The MA.32 randomized controlled trial assigned 3,649 patients with high-risk, non-metastatic breast cancer and no diabetes to metformin or placebo alongside standard therapy. In the hormone-receptor-positive subset the primary endpoint of invasive disease-free survival showed no benefit (HR 1.01, 95% CI 0.84-1.21; P=0.93), and overall survival was likewise unaffected (HR 1.10, 95% CI 0.86-1.41; P=0.47). It is the most rigorous test to date of the widely repeated idea, drawn from observational data, that a diabetes drug treats cancer, and it was null for the main outcomes.
Who this may not transfer to:The trial enrolled a breast-cancer population that is effectively all women; whether metformin affects outcomes in cancers that occur in men is not addressed by this trial.
The study · 1
Goodwin et al., Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial · JAMA 2022;327(20):1963-73
Higher leisure-time activity linked to lower risk of 13 of 26 cancers across 1.44 million adults
In a pooled study of 1.44 million people, being more physically active was linked to a lower risk of 13 of 26 cancers, and the link held whether or not people were lean or smoked.
A pooled analysis of 12 prospective cohorts (1.44 million participants, 186,932 cancers) compared high versus low leisure-time physical activity and found lower risk for 13 of 26 cancer types, including esophageal, liver, lung (HR 0.74), kidney, gastric cardia, endometrial, colon (HR 0.84) and breast (HR 0.90). Most associations persisted after adjustment for body mass index and smoking. Activity was associated with higher risk of malignant melanoma (HR 1.27), likely reflecting sun exposure during outdoor activity.
Who this may not transfer to:Pooled cohorts of both sexes; the associations are for cancer incidence, not for treating a cancer already present.
The study · 1
Moore et al., Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults · JAMA Intern Med 2016;176(6):816-25
Type 2 diabetes roughly doubles the risk of liver, pancreatic and endometrial cancer
People with type 2 diabetes have a higher risk of several cancers, about double for liver, pancreatic and endometrial cancer, though diabetes and obesity share so many causes that untangling them is hard.
A joint consensus report from the American Diabetes Association and the American Cancer Society reviewed the association between diabetes and cancer. It reported type 2 diabetes associated with roughly a twofold higher risk of cancers of the liver, pancreas and endometrium, and a 1.2 to 1.5 fold higher risk of cancers of the colon and rectum, breast and bladder, while risk of prostate cancer was lower in men with diabetes. The report stressed the difficulty of separating the effect of diabetes from the shared upstream risk factors of obesity, aging, physical inactivity and diet.
Who this may not transfer to:Drawn from observational studies of both sexes; prostate risk was lower in men, and the report concerns incidence rather than treatment.
The study · 1
Giovannucci et al., Diabetes and cancer: a consensus report · Diabetes Care 2010;33(7):1674-85
Bariatric surgery tracked with lower cancer incidence, 2.9% vs 4.9% over 10 years
In a large study, adults with obesity who had weight-loss surgery went on to develop and die from obesity-related cancer less often over ten years than similar people who did not have surgery.
The SPLENDID matched-cohort study followed 5,053 adults with obesity who underwent bariatric surgery and 25,265 matched non-surgical patients (median follow-up 6.1 years). Obesity-related cancer incidence at 10 years was 2.9% with surgery versus 4.9% without (adjusted HR 0.68, 95% CI 0.53-0.87), and cancer-related mortality was 0.8% versus 1.4% (adjusted HR 0.52, 95% CI 0.31-0.88). This is evidence that substantial intentional weight loss tracks with lower cancer risk, from surgery rather than diet.
Who this may not transfer to:A mostly female surgical cohort (77% women); the result is about lower cancer risk after major weight loss, not treatment of an existing cancer.
The study · 1
Aminian et al., Association of bariatric surgery with cancer risk and mortality in adults with obesity · JAMA 2022;327(24):2423-33
No adequate human evidence that a ketogenic diet slows tumor growth or improves survival
There is no adequate human evidence that a ketogenic diet treats or cures cancer. Reviews of the trials so far find it feasible for some patients but unproven as a therapy.
A 2021 systematic review and meta-analysis of low-carbohydrate ketogenic diets as adjuvant cancer therapy found inadequate evidence to support beneficial antitumor effects; body weight, total cholesterol and fasting glucose did not shift meaningfully, and only ketosis achievement, satisfaction and a fall in the PSA marker reached significance. A 2017 systematic review of isocaloric ketogenic regimes reached the same conclusion, that evidence supporting effects on tumor development or progression is absent and more robust clinical data are needed before the diet can be recommended for any cancer. Trials were small, short and heterogeneous, and strict ketogenic adherence during treatment is difficult.
Who this may not transfer to:Trials pooled mixed cancer types and both sexes, so the finding is about ketogenic diets as cancer therapy in general rather than any one cancer.
The studies · 2
Yang et al., Efficacy of low-carbohydrate ketogenic diet as an adjuvant cancer therapy: a systematic review and meta-analysis · Nutrients 2021;13(5):1388
Erickson et al., Systematic review: isocaloric ketogenic dietary regimes for cancer patients · Med Oncol 2017;34(5):72
Fasting-mimicking diet during chemotherapy improved radiological tumor response (intention-to-treat) in 131 patients; a pathological response reached significance only per-protocol
In a small trial, a fasting-mimicking diet during chemotherapy improved the radiological tumor response overall (in the intention-to-treat analysis), while a stronger pathological response showed up only in the patients who kept to the diet. It is a lead for larger trials, not a proven treatment.
The phase 2 DIRECT trial randomized 131 patients with HER2-negative stage II/III breast cancer to a fasting-mimicking diet or a regular diet around neoadjuvant chemotherapy. Toxicity did not differ between the groups. The radiological response was better with the diet in the intention-to-treat and multivariable-adjusted analyzes (OR 3.2, P=0.039), while the pathological response defined as 90-100% tumor cell loss reached significance only in the per-protocol analysis (OR 4.1, P=0.016), and the diet reduced chemotherapy-induced DNA damage in T-lymphocytes. As a small phase 2 trial whose pathological signal rests on per-protocol analysis, it is a hypothesis for larger trials to test, not evidence that diet treats cancer.
Who this may not transfer to:A breast-cancer population that is effectively all women; the trial says nothing about fasting-mimicking diets in other cancers or in men.
The study · 1
de Groot et al., Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial · Nat Commun 2020;11(1):3083
The two mechanism findings are graded strong and marked as established biology, because the Warburg effect and metabolic reprogramming are not in dispute. The findings on diet as treatment are graded down to preliminary or read as not established, because the human trials are not there. The grades are deliberately uneven: the mechanism being well established does not carry the treatment claim with it.
What lowers the risk
Metabolism does connect to cancer, firmly, at a stage the diet claims skip past: the risk of developing cancer in the first place. This is where the evidence is strongest, and it is about metabolic health built up over years.
Excess body fat is one of the most established modifiable cancer risk factors there is. The International Agency for Research on Cancer judged the evidence sufficient that absence of excess body fat lowers the risk of thirteen cancers, among them cancers of the colon, kidney, pancreas, liver, endometrium, esophagus and postmenopausal breast. Type 2 diabetes tracks with higher risk of several of the same cancers, roughly doubled for liver, pancreatic and endometrial cancer, though diabetes and obesity share so many risk factors that separating their contributions is difficult.
Physical activity points the other way. Pooling 1.44 million adults, more leisure-time physical activity was associated with lower risk of 13 of 26 cancers, and the associations held regardless of body size and smoking. The sharpest evidence that shifting metabolic health changes cancer outcomes comes from large intentional weight loss: in a matched cohort of adults with obesity, those who had bariatric surgery had lower cancer incidence and lower cancer mortality over ten years. These come from observational and surgical studies, not from diet trials, and they point at metabolic health mattering for risk, a separate question from any diet treating a cancer that already exists.
Keeping a healthy weight, staying active and looking after insulin and glucose handling is a well-evidenced way to lower the chance of getting several cancers. It is not a way to treat one. The two questions get answered by different bodies of evidence, and the diet claims blur them, presenting the prevention evidence as if it showed treatment.
For People In Treatment
Go Deeper
The biology this page describes runs through processes covered in their own right, and the levers that actually track with lower risk have their own pages:
- Mitochondria and energy, the machinery behind the Warburg effect, and insulin and glucose, which explains why blood glucose stays regulated whatever you eat.
- The ketogenic diet, graded on its own evidence, and whole foods, the dietary pattern with the broadest support.
- Weight and metabolic health, where the risk side of this page is covered in full.
Common Questions
Does sugar feed cancer?
Tumor cells do take up a lot of glucose, which is the true fact behind the slogan. What does not follow is that eating sugar feeds a tumor or that cutting it will starve one. Your body holds blood glucose in a narrow range whatever you eat, so a tumor draws roughly the same supply either way. Sugar can raise cancer risk over years by driving weight gain, which is a different pathway from feeding a tumor at the table.
Can a ketogenic diet treat or cure cancer?
Not on the current human evidence. Systematic reviews of ketogenic diets in cancer patients have found no adequate evidence that the diet slows tumor growth or improves survival, and no trial shows it eliminates cancer. There are preclinical signals and ongoing studies, so the question is open, but the treatment claim is not established. Used as a substitute for proven treatment, the diet can cause real harm.
Is cancer a metabolic disease?
There is a serious minority view, associated with Thomas Seyfried, that cancer is primarily metabolic, against the mainstream view that mutations drive it with metabolism reprogrammed downstream. The metabolic theory has generated testable hypotheses. On the question that matters to a patient, whether a metabolic diet treats cancer, the human trials have not supported it.
If metabolism does not treat cancer, why does it matter?
Because metabolic health strongly affects the risk of getting several cancers. Excess body fat is a cause of thirteen cancers by IARC's assessment, physical activity is associated with lower risk of many, and large weight loss tracks with lower incidence. Keeping a healthy weight and staying active is well-evidenced prevention. That is a separate question from treating an existing cancer, which these habits are not shown to do.
Should someone in treatment try fasting or keto?
Not on their own, and not as a replacement for treatment. Fasting-mimicking diets around chemotherapy are experimental and can be unsafe for anyone at risk of weight loss or malnutrition. Any dietary change during cancer treatment is a question for the oncology team, whose plan should stay the priority.
The Chinese Medicine Reading
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 10 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.